Boston Scientific downgraded to Market Perform from Outperform at Bernstein

theflyonthewall.com

Bernstein downgraded Boston Scientific citing continued share losses in its major cardiology business, lack of catalysts, and secular pressure in the drug eluting stent market. Price target remains $6.

Rates

View Comments (0)